IN THE DRAWINGS:

Subject to the approval of the Examiner, please replace Figures 1 and 2, as filed with this reissue application, with the enclosed Figures 1 and 2.

IN THE CLAIMS:

Please amend claims 2-14 as follows:

2. (Twice Amended) [An] The adenovirus according to claim 1, wherein the EBV antigen is EBNA 1.

3. (Amended) [An] The An adenovirus according to claim 2, wherein the expression signal consists of a chimeric promoter comprising a sequence which is activated by EBNA 1 antigen fused upstream of a viral promoter.

4. (Amended) [An] The adenovirus according to claim 1, lacking regions of its genome which are required for replication in a target cell.

A2

5. (Amended) [An] The adenovirus according to claim 4, wherein said adenovirus is a type Ad5 human adenovirus or a type CAV-2 canine adenovirus.

6. (Amended) [An] The adenovirus according to claim 1, wherein the heterologous DNA sequence comprises a gene which encodes a product toxic in a cell infected by said adenovirus.

7. (Amended) [An] The adenovirus according to claim 6, wherein said product renders said cell sensitive to a therapeutic agent.

8. (Amended) [An] The adenovirus according to claim 7, wherein the gene is the thymidine kinase gene and the therapeutic agent is ganciclovir or acyclovir.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com